Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Biodesix Inc

Current price
1.49 USD 0 USD (0.00%)
Last closed 1.49 USD
Sector Healthcare
Industry Diagnostics & Research
Exchange NASDAQ
Capitalization 134 809 696 USD
Yield for 12 month +4.20 %
21.11.2021 - 28.11.2021

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a blood-based NGS. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado. Address: 2970 Wilderness Place, Boulder, CO, United States, 80301


WallStreet Target Price

4.25 USD

P/E ratio

Dividend Yield

Current Year

+38 212 000 USD

Last Year

+54 506 000 USD

Current Quarter

+13 491 000 USD

Last Quarter

+11 872 000 USD

Current Year

+24 058 000 USD

Last Year

+23 988 000 USD

Current Quarter

+10 262 000 USD

Last Quarter

+8 634 000 USD

Key Figures BDSX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -45 093 000 USD
Operating Margin TTM -53.16 %
PE Ratio
Return On Assets TTM -40.29 %
PEG Ratio
Return On Equity TTM -19497.05 %
Wall Street Target Price 4.25 USD
Revenue TTM 44 026 000 USD
Book Value -0.016 USD
Revenue Per Share TTM 0.6 USD
Dividend Share
Quarterly Revenue Growth YOY 21.5 %
Dividend Yield
Gross Profit TTM 24 058 000 USD
Earnings Share -0.88 USD
Diluted Eps TTM -0.88 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -143.88 %

Dividend Analytics BDSX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BDSX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation BDSX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 3.7435
Price Sales TTM 3.062
Enterprise Value EBITDA -3.4523
Price Book MRQ 6.5465

Financials BDSX

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators BDSX

For 52 weeks

1.03 USD 2.53 USD
50 Day MA 1.54 USD
Shares Short Prior Month 136 768
200 Day MA 1.53 USD
Short Ratio 3.56
Shares Short 157 313
Short Percent 0.37 %